Even the AIDS vaccine world has jumped on the simplicity bandwagon. To many AIDS vaccine researchers, the key obstacle is that no one has yet found a vaccine that can trigger effective antibodies against the surface protein of the virus. So Merck has constructed a vaccine that abandons antibodies altogether, and the company is testing it in a fast-tracked study to determine whether it's worth pursuing the approach.
No takes yet. Share an insight, caveat, or question.
Jon Cohen (2005) studied this question.